Skip to main content
. 2013 Aug 15;170(1):101–126. doi: 10.1111/bph.12248

Table 1.

Binding affinities from site directed mutagenesis studies on histamine receptors and crystallized aminergic GPCRs

Ligand Reference WT 2.57 2.61 2.64 3.24 3.28 3.32 3.33 3.36 3.37 3.40 4.57 45.49 45.50 45.51 5.39 5.42 5.43 5.46 6.48 6.51 6.52 6.55 7.31 7.39 7.42
Histamine H1 receptor V N Y L W D Y S T I V K C E K T A N W Y F F N I G
8 Moguilevsky et al. (1995) 5.9 5.2 (A) 3.6 (A)
19 Moguilevsky et al. (1995) 7.0 8.0 (A)
8 Gillard et al. (2002) 5.9 4.7 (A) 5.2 (A)
18 Gillard et al. (2002) 8.5 7.9 (A) 8.7 (A)
19 Gillard et al. (2002) 7.1 6.3 (A) 8.2 (A)
16 Nonaka et al. (1998) 8.6 7.3 (A) 8.4 (A) 8.4 (A)
1 Nonaka et al. (1998) 9.2 6.7 (A)
8 Ohta et al. (1994) 4.8 N.D. (A) 4.2 (A) <2.0 (A)
8 Bruysters et al. (2004) 4.3 N.D. (A) 3.9 (A) 2.6 (A) N.D. (A) 2.7 (A)
8 Wieland et al. (1999) a 4.1 3.5 (A) 3.7 (M) 4.5 (M)
17 Wieland et al. (1999) a 8.0 6.3 (A)
19 Wieland et al. (1999) a 7.2 6.3 (A)
8 Leurs et al. (1995) a 4.5 3.8 (A)
9 Leurs et al. (1994) a 9.1 9.3 (A) 8.3 (A)
12 Leurs et al. (1994) a 7.2 7.4 (A) 6.5 (A)
8 Bakker et al. (2004) 4.2 <2.2 (A) 3.7 (A) 3.0 (A)
Histamine H2 receptor V S Y F Y D V C T I S K C K G D G T W Y F F N L G
8 Gantz et al. (1992) b - ↓ (N) ↓ (A) ↓ (A)
Histamine H3 receptor C Y Y L W D Y C T A Y H C Y L A S E W Y T M P F L
8 Uveges et al. (2002) 7.8 7.7 (A) 7.2 (Q) 4.5 (A)
29 Yao et al. (2003) 9.4 9.1 (A) 10.5 (V)
21 Yao et al. (2003) 7.2 8.2 (A) 8.4 (V)
22 Yao et al. (2003) 6.1 7.6 (A) 7.4 (V)
Histamine H4 receptor S Y H I W D Y C T V N E C E L T S E W Y S T K F Q
31 Schultes et al. (2012) 7.1 6.5 (V) 6.7 (Q)
32 Schultes et al. (2012) 7.7 6.4 (V) 7.5 (Q)
33 Schultes et al. (2012) 8.3 7.7 (V) 7.2 (Q)
34 Schultes et al. (2012) 8.7 7.2 (V) 6.7 (Q)
29 Istyastono et al. (2011b) 8.1 8.0 (A) 7.8 (Y) 8.6 (A) 7.3 (Q) 8.8 (M) 9.0 (L)
30 Istyastono et al. (2011b) 7.5 7.2 (A) 6.5 (Y) 7.9 (A) 6.8 (Q) 7.9 (M) 7.9 (L)
8 Jongejan et al. (2008) 7.7 N.D. (A) 5.0 (Q)
48 Jongejan et al. (2008) 6.3 N.D. (A) 6,2 (Q)
48 Lim et al. (2010) 6.4 4.7 (H) 7.0 (V) 6.6 (L)
32 Lim et al. (2010) 8.3 7.7 (H) 7.1 (V) 7.8 (L)
8 Shin et al. (2002) 7.8 N.D. (A) 7.5 (T) 7.3 (A) 7.5 (A) N.D. (A) 7.1 (F)
8 Shin et al. (2002) 7.8 N.D. (E) 7.2 (A) 6.8 (D) 7.5 (A)
8 Shin et al. (2002) 7.8 N.D. (N) N.D. (N)
Dopamine D3 receptor V V L C F D V C T I S V C S V S S S W F F H S T G
35 Dorfler et al. (2008) 7.1 6.0 (E) <4.1 (W)
37 Dorfler et al. (2008) 8.4 5.9 (E) 6.6 (W)
38 Dorfler et al. (2008) 8.6 5.8 (E) 7.5 (W)
39 Ehrlich et al. (2009) 6.1 5.6 (F) 6.1 (F) 6.2 (E) 7.2 (A)
40 Ehrlich et al. (2009) 7.6 6.1 (F) 6.4 (F) 6.2 (E) 7.9 (A)
35 Alberts et al. (1998) 8.4 7.0 (S)
36 Lundstrom et al. (1998) 8.6 8.8 (H) 7.6 (L) 8.7 (A) 9.1 (V)
37 Lundstrom et al. (1998) 8.3 8.9 (H) 8.4 (L) 8.6 (A) 9.3 (V)
35 Lundstrom et al. (1998) 7.2 7.1 (H) 6.0 (L) 7.1 (A) 7.9 (V)
41 Lundstrom et al. (1998) 8.6 9.1 (H) 7.9 (L) 9.1 (A) 9.4 (V)
35 Sartania and Strange (1999) 7.4 5.7 (A) 7.1 (A) 7.5 (A)
Muscarinic M2 receptor S Y Y V W D Y S N V W E C Y T T A A W Y N V P Y C
44 Gregory et al. (2010) 10.0 9.6 (A) 9.6 (A) 8.4 (A) 9.7 (A) 10.0 (A) 9.49 (A)
42 Gregory et al. (2010) 5.1 4.9 (A) 4.5 (A) 2.5 (A) 3.8 (A) 5.0 (A) 3.06 (A)
49 Gregory et al. (2010) 5.7 7.1 (A) 8.8 (A) 5.2 (A) 5.7 (A) 6.2 (A) 6.27 (A)
47 Gregory et al. (2010) 6.2 5.9 (A) 6.3 (A) 5.8 (A) 5.7 (A) 6.2 (A) 5.85 (A)
45 Heitz et al. (1999) 9.6 9.6 (A) N.D. (A) N.D. (A) 9.1 (A) 9.3 (A) N.D. (A) N.D. (A) N.D. (A)
44 Heitz et al. (1999) 9.7 9.4 (A) N.D. (A) 8.5 (A) 9.0 (A) 9.8 (A) 9.1 (A) N.D. (A) N.D. (A)
42 Hulme et al. (1995) 5.6 3.6 (E)
Muscarinic M3 receptor S F Y A W D Y S N V W E C F T T A A W Y N V P Y C
45 Schmidt et al. (2003) c 9.3 10.0 (A) 8.5 (T) 9.6 (I)
42 Wess et al. (1993) c 6.1 4.8 (F)
45 Wess et al. (1991) c 10.3 9.3 (A) 9.9 (F) 10.4 (A) 10.3 (A) 10.1 (F) 9.7 (F)
42 Wess et al. (1991) c 5.8 5.4 (A) 4.7 (F) 4.7 (A) 4.2 (A) 4.1 (F) 4.4 (F)
42 Bluml et al. (1994) c 5.7 5.0 (A)
43 Bluml et al. (1994) c 10.5 9.5 (D)
46 Bluml et al. (1994) c 11.0 6.5 (D)
β2 adrenoceptor V G H W W D V V T I S C C D A S S S W F F N R N G
7 Dohlman et al. (1990) 9.9 8.5 (V) 8.5 (V)
50 Dohlman et al. (1990) 8.4 6.8 (V) 6.2 (V)
52 Dohlman et al. (1990) 8.2 6.9 (V) 6.9 (V)
53 Dohlman et al. (1990) 9.4 7.3 (V) 7.2 (V)
7 Fraser (1989) 8.0 7.2 (S) 5.2 (S)
50 Fraser (1989) 6.7 4.7 (S) 4.3 (S)
56 Fraser (1989) 9.7 7.7 (S) 6.2 (S)
55 Fraser (1989) 7.7 5.5 (S) 5.0 (S)
53 Liapakis et al. (2000) 6.9 6.5 (T) 5.4 (A)
7 Suryanarayana and Kobilka (1993) 6.3 4.2 (T)
54 Suryanarayana and Kobilka (1993) 5.7 4.0 (T)
51 Ambrosio et al. (2000) 6.7 5.3 (A) 5.5 (A)
7 Wieland et al. (1996) 6.6 6.7 (A) 5.6 (L)
50 Wieland et al. (1996) 5.0 5.1 (A) 4.8 (L)
54 Wieland et al. (1996) 6.8 5.2 (L)

The annotated binding affinities (pIC50/pKi) for the mutants are followed by their respective mutation in brackets. Human (unless otherwise specified) SDM binding affinity data was collected from GPCRdb (Vroling et al., 2011) and an exhaustive literature search. The complete overview is available in the supporting information (Table S1) from which a subselection of single-point mutations within the predefined binding pocket is presented here.

a

SDM study on guinea pig H1R.

b

Only functional SDM data available for histamine (8) in H2R (Gantz et al., 1992).

c

SDM study on rat M3R.